#NEWS: Today we announced our full year 2024 financial results and updates on corporate developments. Key take-aways include: - A strategic transformation to focus on VTP-1000, our potentially curative immunotherapy for celiac disease, positioning us to become a leader in immunological and inflammatory diseases - A renewed emphasis on promoting antigen-specific immune tolerance VTP-1000 advanced into the clinic, and first data from the Phase 1 AVALON trial is expected in H2 2025 - Our proprietary SNAP-TI platform technology designed to promote immune tolerance is driving multiple future pipeline and partnership opportunities - Strong financial position with cash runway extended into 2027 Read the full release here: http://bit.ly/41H9MvP #BRNS #Biotech #CeliacDisease #Innovation
Barinthus Biotherapeutics
Biotechnology Research
Harwell, Oxfordshire 9,997 followers
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.
About us
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI; Barinthus Biotherapeutics is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Biotherapeutics’ proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives.
- Website
-
https://www.barinthusbio.com
External link for Barinthus Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Harwell, Oxfordshire
- Type
- Public Company
- Founded
- 2016
- Specialties
- Research, Immunotherapy, Infectious Disease, Oncology, Viral vectors, HBV, HPV, Prostate cancer, Non-small cell lung cancer, Hepatitis B, Celiac, SNAP, and nanoparticles
Locations
-
Primary
Get directions
Units 6-10 Zeus Building, Rutherford Avenue
Harwell, Oxfordshire OX11 0DF, GB
-
Get directions
20400 Century Blvd
Suite 210
Germantown, Maryland 20874, US
Employees at Barinthus Biotherapeutics
-
Nick Fullenkamp
Vice President of Corporate Development at Barinthus Biotherapeutics
-
Katie Anderson
Senior Director | Team Leader | Project Manager | Immunology | Biomarkers | Immunotherapies | GCP
-
Dominick J. Laddy, Ph.D., P.M.P.
Director, Program Management | Immunology Expertise
-
Nadege Pelletier
Chief Scientific Officer at Barinthus Bio
Updates
-
SNAP-TI is our proprietary platform technology for promoting antigen-specific immune tolerance with a broad range of potential applications. The platform leverages self-assembly to co-deliver multiple antigens and an immunomodulator in nanoparticles. Find out more at: https://lnkd.in/eUcwaqdp #biotech #BRNS
-
We're kicking off 2025 with investor meetings in San Francisco for JPM Week. Reach out to us at ir@barinthusbio.com or get in touch with the team on the ground: Bill Enright, Gemma Brown, Geoffrey M. Lynn, MD, PhD, Nick Fullenkamp and Nadege Pelletier. See you there! #JPM25 #BRNS #biotech #SanFran
The countdown is on! We're kicking off 2025 by hosting #Investor meetings in San Francisco during JPM Week. To schedule a meeting, you can register at: https://lnkd.in/eRDhJvqJ Or you can contact us directly if you aren’t attending but would still like a catch-up call. #JPM25 #Biotech #Teambarinthus #BRNS
-
-
The countdown is on! We're kicking off 2025 by hosting #Investor meetings in San Francisco during JPM Week. To schedule a meeting, you can register at: https://lnkd.in/eRDhJvqJ Or you can contact us directly if you aren’t attending but would still like a catch-up call. #JPM25 #Biotech #Teambarinthus #BRNS
-
-
#NEWS: We named Geoffrey M. Lynn, MD, PhD as our Chief Scientific Officer. Dr. Lynn, also the co-inventor of SNAP-TI, brings more than 15 years of experience leading immunotherapeutic R&D from discovery through early development. Dr. Lynn will transition to his new role starting December 1, 2024. Read the full release: https://lnkd.in/emyG-S-z #immunotherapy #celiacdisease #biotechnews #healthcare #innovation #cso #leadership #csuite
-
Our VP of Research, Sarah Sebastian, will be presenting at the British Society for Immunology Immune Therapies Summit on Monday 25 November, talking about antigen-specific tolerance induction via our proprietary SNAP-TI platform. Read more here: https://lnkd.in/eyH5mjma #innovation #immunotherapy #biotech #WomenInSTEM
-
-
#NEWS: Today we shared positive results from two ongoing chronic hepatitis b #clinicaltrials, with data showing patients who met the criteria for functional cure. We will be presenting late-breaking data from both our Phase 2b HBV003 and the IM-PROVE II trials at AASLD - The Liver Meeting®. These data sets bring us a step closer to potentially allowing some patients with chronic #hepB to discontinue life-long antiviral treatments. Read more here: https://lnkd.in/eyTh5gJn #TLM24 #AASLD24 #hepatitis #BiotechNews
-
-
For #investors and #partners: Meet with us at Jefferies London Healthcare Conference! We’ll have our latest #hepatitisB data from AASLD 2024 to talk to and will be available for one-on-one meetings starting November 19. Reach out to us to schedule a meeting and learn more here: https://lnkd.in/e8HfvqCc #JefferiesHealthcare #partnering #immunotherapy
-
-
We’re at Guggenheim Partners Healthcare Talks Conference today. Watch our CEO Bill Enright’s fireside chat at 14:00 ET to get the latest update on Barinthus Bio’s innovative technology. Watch it here: https://lnkd.in/eS-86F8w
-
-
The countdown to AASLD - The Liver Meeting® is on! In one week, we’ll share updated #data from our #clinicaltrials HBV003 and IM-PROVE II in #hepatitis B. Read more about the #innovation within our viral vector platform: https://lnkd.in/eJXwNUNT #TLM24 #AASLD24 #healthcare
-